Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: a pooled analysis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F19%3AE0108006" target="_blank" >RIV/00843989:_____/19:E0108006 - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/19:A21025QX

Result on the web

<a href="https://www.mdpi.com/2072-6694/11/11/1735" target="_blank" >https://www.mdpi.com/2072-6694/11/11/1735</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/cancers11111735" target="_blank" >10.3390/cancers11111735</a>

Result language

angličtina

Original language name

Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: a pooled analysis

Original language description

We conducted a pooled analysis of two phase III trials, RV-MM-EMN-441 and EMN01, to compare maintenance with lenalidomide-prednisone vs. lenalidomide in newly diagnosed transplant-eligible and -ineligible myeloma patients. Primary endpoints were progression-free survival, progression-free survival 2 and overall survival with both regimens. A secondary aim was to evaluate the impact of duration of maintenance on overall survival and on outcome after relapse. A total of 625 patients (lenalidomide-prednisone arm, n = 315; lenalidomide arm, n = 310) were analyzed. The median follow-up was 58 months. Median progression-free survival (25 vs. 19 months; p = 0.08), progression-free survival 2 (56 vs. 49 months; p = 0.9) and overall survival (73 months vs. NR; p = 0.08) were not significantly different between the two arms. Toxicity profiles of lenalidomide-prednisone and lenalidomide were similar, with the exception of neutropenia that was higher in the lenalidomide arm (grade ? 3: 9% vs. 19%, p < 0.001), without an increase in the rate of infections. Overall survival (median NR vs. 49 months, p < 0.001), progression-free survival from relapse (median 35 vs. 24 months, p = 0.004) and overall survival from relapse (median not reached vs. 41 months, p = 0.002) were significantly longer in patients continuing maintenance for ?2 years. We showed that the addition of prednisone at 25 or 50 mg every other day (eod) to lenalidomide maintenance did not induce any significant advantage.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cancers

ISSN

2072-6694

e-ISSN

—

Volume of the periodical

11

Issue of the periodical within the volume

11

Country of publishing house

CH - SWITZERLAND

Number of pages

1735

Pages from-to

1735

UT code for WoS article

000502290100117

EID of the result in the Scopus database

2-s2.0-85076548260